Top Markets
#1 PumpMeme PumpMeme +1,053.55%
#2 ALEO ALEO +71.52%
#3 Siren Siren +31.74%
#4 World Mobile Token World Mobile Token +30.46%
#5 peaq peaq +27.38%
#6 Quant Quant +27.34%
#7 Ondo Ondo +26.56%
#8 CZ'S Dog CZ'S Dog +26.20%
#9 Wrapped XPL Wrapped XPL +24.78%
#10 Unit Plasma Unit Plasma +24.68%
Coin of the day
PumpMeme PumpMeme
Settings
Language
ENGLISH
Currency
USD
Theme
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Rank in Stocks #31262
Noxopharm Limited is an Australian drug development company with an... Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer. The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries. Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma. Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.
Share Price
$0.04443294
Market Cap
$13.65M
Change (1 day)
0.00%
Change (1 year)
-32.53%
Country
AU
Trade Noxopharm Limited (NOX)

Category

Healthcare
P/E ratio for Noxopharm Limited (NOX)
P/E ratio as of September 2026 TTM: -4.90
According to Noxopharm Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.90. At the end of 2024 the company had a P/E ratio of -5.39.
P/E ratio history for Noxopharm Limited from 2016 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -4.90 51.76%
2025 -3.23 -40.02%
2024 -5.39 545.91%
2023 -0.83 -72.57%
2022 -3.04 -83.29%
2021 -18.21 -78.30%
2020 -83.90 1,577.80%
2019 -5.00 42.59%
2018 -3.51 -62.16%
2017 -9.27 19.11%
2016 -7.78 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.99 -711.89%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -18.38 274.99%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.34 376.08%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.30 -840.42%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.